• Paxman expanded UKCA, CE, ISO 13485, and MDSAP certification scope to cover its new cryocompression device for chemotherapy-induced peripheral neuropathy.
• The move supports regulatory pathways in the UK and EU, positioning the technology for potential approvals in the US and other major markets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Paxman AB published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.